Mendus

Company Description

---

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST.

Served area

---

Europe

Headquarters

---

Västra Trädgårdsgatan 15, 11153 Stockholm – Sweden

Shares outstanding

---

199,400,599

IPO

---

Jan. 1, 2000

Stock exchange(s)

---

Nasdaq Stockholm